



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/930,915	08/15/2001	Ashley J. Birkett	LOR-102.2 (81175)	2278

24628 7590 03/04/2009  
Husch Blackwell Sanders, LLP  
Husch Blackwell Sanders LLP Welsh & Katz  
120 S RIVERSIDE PLAZA  
22ND FLOOR  
CHICAGO, IL 60606

EXAMINER
----------

PENG, BO

ART UNIT	PAPER NUMBER
----------	--------------

1648

MAIL DATE	DELIVERY MODE
-----------	---------------

03/04/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 09/930,915	<b>Applicant(s)</b> BIRKETT, ASHLEY J.	
	<b>Examiner</b> BO PENG	<b>Art Unit</b> 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 02 January 2009.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 1-9, 12-33, 35-38 and 42-78 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-9, 12-33, 35-38 and 42-78 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

1. Upon further consideration of this application, the examiner has determined that it is necessary to vacate the previous Office action dated February 18, 2009. The period for reply of 3 MONTHS set in said Office action is restarted to begin with the mailing date of this Office action. The examiner regrets any inconvenience this may cause Applicant.
2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 2, 2009, has been entered.
3. Claims 1-9, 12-33, 35-38 and 42-78 are pending, and are under consideration in this Office action.

### ***Specification***

4. **(Prior objection-withdrawn)** The objection to the specification for the use of trademarks is withdrawn in view of Applicant's argument.

### ***Claim Rejections – 35 USC § 112-Scope of enablement***

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the

Art Unit: 1648

art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. **(Prior rejection-maintained)** The rejection of Claims 1-9, 12-33, 35-38 and 42-78 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement (scope of enablement), **is maintained** for the reasons set forth in the Office action date August 4, 2008, see Para 5-9.

In response to Applicant's argument:

7. Applicant argues that the specification enables the scope of the claims because specification teaches use of LASERGENE software to assist in determining which amino acid residues can be conservatively changed without a loss of biological activity or the ability to form particles.

8. This argument is not convincing. While a computer program may help one of ordinary skill in the art to chose which amino acids could be altered, such general direction is not sufficient to predict if the proposed changes would actually result in a desired property, such as enhanced stability, of the modified HBc. It is noted that, even with the assistance of LASERGENE software, the specification has shown that modified HBc chimers containing changes of two or three amino acids (less than 5% substitution of amino acid residues in the HBc SEQ ID NO: 246-251), totally abolish their ability to form particles, See example 14 and table 13. Thus, the specification apparently does not support applicants' argument. The rejection is maintained.

9. **(New rejection)** Claims 1-9, 12-33, 35-38 and 42-78 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such

Art Unit: 1648

a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The following quotation from section 2163 of the Manual of Patent Examination Procedure is a brief discussion of what is required in a specification to satisfy the 35 U.S.C. 112 written description requirement for a generic claim covering several distinct inventions:

The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice..., reduction to drawings..., or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus... See *Eli Lilly*, 119 F.3d at 1568, 43 USPQ2d at 1406.

A "representative number of species" means that the species which are adequately described are representative of the entire genus. Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus.

It is also noted that even the presence of multiple species within a claimed genus does not necessarily demonstrate possession of the genus. See, *In re Smyth*, 178 U.S.P.Q. 279 at 284-85 (CCPA 1973) (stating "where **there is unpredictability in performance of certain species or subcombinations other than those specifically enumerated**, one skilled in the art may be found not to have been placed in possession of a genus or combination claimed at a later date in the prosecution of a patent application."); and *University of California v. Eli Lilly and Co.*, 43 USPQ2d 1398, at 1405 (Fed Cir 1997)(citing *Smyth* for support). Thus, when a claim covers a genus of inventions, the specification must provide sufficient written description support for the entire scope of

Art Unit: 1648

the genus. Support for a genus is generally found where the applicant has provided a sufficient number of examples so that one skilled in the art would recognize from the specification the scope of what is being claimed, or provided a function and a structure correlating with that function. Moreover, in situations where the operability of species other than those provided is uncertain, additional support is required over that which would be required where greater certainty is present.

10. The scope of the claims encompasses a large number of HBc chimers that contain a 5% substitution frequency in SEQ ID No: 246-251(183 amino acids). The claims further require that the specified HBc particle has enhanced stability comparing to wt HBc. In support of the claims, the specification shows a few species of HBc chimer (for example, 7 of 24 chimers in Example 14) were able to yield particles, see Table 13, Example 14. Of the modified HBc chimers in the above example, however, 14 of the 24 tested lost their ability to form particles. Thus, the specification shows that it is uncertain if HBc chimers containing a 5% substitution frequency in SEQ ID No: 246-251 can form viral-like particles as can HBc, or would the resultant HBc particles have enhanced stability as claimed.

11. The art indicates that the result of peptide modification is, in general, unpredictable. Modification of a peptide by as little as one amino acid can cause a change in conformation, and thus peptide function, that can't be predicted in advance. See Rudinger, J. at page 6 (Cited in the previous Office action). Metzger teaches that a single amino acid change, Pro-138 to Gly, prevents self-assembly of the HBc protein into particles (Metzger, J. Gen. Virology, 79:587-590, 1998, cited in the Office action dated August 4, 2008). Thus, substitution of a single amino acid can result in an unpredictable

Art Unit: 1648

effect on the assembly of HBc particles. These teachings in the art are consistent with the result shown in the specification Example 14.

13. Although the specification discloses a few species of modified HBc chimers, the specification has also illustrated that most amino acid changes in HBc result in an inability to form particles. The specification has failed to provide an adequate description which amino acid substitution in the HBc chimers can still form viral-like particles, and has enhanced stability comparing to wt HBc. Given that the scope of the claims encompasses a large number of modified HBc chimers, and considering the unpredictable stability of the majority of modified HBC chimers, the specification has not disclosed sufficient species of modified HBc chimers that have enhanced stability to support the broadly claimed genus. Consequently, the skilled artisan would reasonably conclude Applicant was not in possession of the claimed HBc chimers that have both 5% substitution of amino acid residues in the HBc SEQ ID NO: 246-251, and enhanced stability.

### ***Claim Rejections - 35 USC § 103***

14. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Art Unit: 1648

15. **(Prior rejection-maintained)** The rejection of Claims 1-9, 15, 16, 18-26, 30-33, 35, 38, 42-58, 63-75, 77 and 78 under 35 U.S.C. 103(a), as being unpatentable over Pumpens *et al.* (1995) in view of Zlotnick *et al* (1997), **is maintained** for the reasons of record.

16. Applicant argues that the Zlotnick manuscript is not valid in support of the premise that C-terminal cysteines enhance stability because it lacks proper controls and therefore conclusions gleaned from it are suspect.

17. This argument is not convincing. The Zlotnick manuscript is published in a peer-reviewed scientific journal. This fact indicates that one of ordinary skill in the art has accepted the evidence and conclusions presented in the Zlotnick manuscript. It is noted that the instant specification also recited the Zlotnick manuscript as analogous art, see Para [0009]. Thus, Applicant's argument is not convincing.

18. **(Prior rejection-maintained)** The rejection of Claims 12-14, 17, 27-29, 36, 37, 59-62 and 76 under 35 U.S.C. 103(a), as being unpatentable over Pumpens *et al.* (1995), in view of Zlotnick *et al* (1997) as applied to Claims 1-9, 15, 16, 18-26, 30-33, 35, 38, 42-58, 63-75, 77 and 78, further in view of Thornton *et al.* (US 5,143,726) **is maintained** for the same reasons of record.

19. Applicant argues that Thornton teaches that HBcAg protein operatively linked though an amino acid residue side chain to a polypeptide immunogen. In contrast, the present invention does not utilize an endogenous amino acid side chain for linking. The

Art Unit: 1648

present invention utilizes a heterologous linker residue (see Claim 12). Therefore, Thornton's teaching is different from that used in the present application.

20. This argument has been considered but found not persuasive. The test for obviousness is not whether the features of a secondary reference may be bodily incorporated into the structure of the primary reference; nor is it that the claimed invention must be expressly suggested in any one or all of the references. Rather, the test is what the combined teachings of the references would have suggested to those of ordinary skill in the art. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981). According to M.P.E.P. § 2143.02, "Obviousness does not require absolute predictability, however, at least some degree of predictability is required. Evidence showing there was no reasonable expectation of success may support a conclusion of nonobviousness. *In re Rinehart*, 531 F.2d 1048, 189 USPQ 143 (CCPA 1976)." In the recently decided case of *KSR International Co. v. Teleflex Inc.* (82 U.S.P.Q. 2d1385, 2007), the Supreme Court provided a number of bases on which a claimed invention may be found obvious. In particular, "When there is a design need or market pressure to solve a problem and there are a finite number of identified predictable potential solutions, a person of ordinary skill has good reason to pursue the known potential options within his or her technical grasp. If this leads to the anticipated success, it is likely the product not of innovation but of ordinary skill and common sense". In the present case, the instant claims, such as Claim 12, require said HBc chimera contains a heterologous linker residue for a conjugated epitope. Thornton teaches use of chemically modified residue(s) on HBc for a conjugated epitope, see e.g. Abstract, and last Para, right col. bridge to Para 1, col. 15. Since both the modified HBc residue of the prior art and the "heterologous linker residue" of

Art Unit: 1648

claimed HBc chimer function as a linker of a conjugated epitope, they are considered as functional equivalents “for a conjugated epitope”. There is reasonable expectation of success that a “heterologous linker residue” can link a polypeptide immunogen as well as a modified amino acid residue of HBc of the prior art. Therefore, Applicant’s argument is not found persuasive. The rejection is maintained.

21. **(New rejection)** Claims 12-14, 17, 27-29, 36, 37, 59-62 and 76 are rejected under 35 U.S.C. 103(a), as being unpatentable over Pumpens *et al.* (1995), in view of Zlotnick *et al* (1997), as applied to Claims 1-9, 15, 16, 18-26, 30-33, 35, 38, 42-58, 63-75, 77 and 78, further in view of Birkett (US 6,231,864, cited in IDS).

The applied reference has a common inventor with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art only under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 103(a) might be overcome by: (1) showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not an invention “by another”; (2) showing a date of invention for the claimed subject matter of the application which corresponds to subject matter disclosed but not claimed in the reference, prior to the effective U.S. filing date of the reference under 37 CFR 1.131; or (3) an oath or declaration under 37 CFR 1.130 stating that the application and reference are currently owned by the same party and that the inventor named in the application is the prior inventor under 35 U.S.C. 104, together with a terminal disclaimer in accordance with 37 CFR 1.321(c). This rejection might also be overcome by showing that the

Art Unit: 1648

reference is disqualified under 35 U.S.C. 103(c) as prior art in a rejection under 35 U.S.C. 103(a). See MPEP § 706.02(l)(1) and § 706.02(l)(2).

22. The relevance of Pumpens and Zlotnick is set forth in the previous Office action. However, neither Pumpens nor Zlotnick teaches HBc chimera contains a heterologous linker residue for a conjugated epitope.

23. Birkett teaches a modified hepatitis B core protein comprising a chemically reactive amino acid residue, preferably in an immunodominant region of the nucleocapsid protein. The modified hepatitis B core protein or its aggregated nucleocapsid protein particles can be pendently linked to a hapten to form a modified nucleocapsid conjugate. The modified hepatitis B core protein can also be modified to include a T cell epitope, see e.g. Abstract and claims.

24. One of ordinary skill in the art would have been motivated to combine the teachings of Birkett with that of Pumpens and Zlotnick in order to make an HBc $\Delta$  molecule that could present an epitope *via* a side-chain. One would have been motivated to do so, and would have had a reasonable expectation of success, given the knowledge that both HBc and HBc $\Delta$  have been successfully used for displaying heterologous epitopes at their *N*-, and *C*-termini, and immunodominant loop at positions 76 through 85, as taught by Pumpens and Birkett, and given the knowledge that methods for operatively linking individual haptens to polypeptides through an amino acid residue side chain to form an immunogenic conjugate are well known in the art, as taught by Birkett, see e.g. col. 13 and 14, Therefore the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

### ***Double Patenting***

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

25. **(New rejection)** Claims 1-9, 12-33, 35-38 and 42-78 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over (1) Claims 1-46 of copending Application No. 10/732,862. (2) Claims 1-53 of 10/787,734; (3) Claims 98-109 of 10/805,913; (4) Claims 79-115 of 10/806,006, (5) Claims 47-85 of 11/508,655, and (6) Claims 1-22, 25 and 26 of 11/507,083. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claimed recombinant chimer HBC protein of the instant application are obvious variations of the claimed HBC chimer of the reference claims.
26. This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

27. **(New rejection)** Claims 1-9, 12-33, 35-38 and 42-78 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-19 of U.S. Patent No. 6,231,864 ('864), in view of Zlotnick (PNAS,1997, 94(18):9556-61; cited in the previous Office action).

28. Claims 1-9 of '864 teach a modified hepatitis B core protein comprising a chemically reactive amino acid residue, preferably in an immunodominant region of the nucleocapsid protein. The modified hepatitis B core protein or its aggregated nucleocapsid protein particles can be pendently linked to a hapten to form a modified nucleocapsid conjugate. The modified hepatitis B core protein can also be modified to include a T cell epitope.

29. Zlotnick teaches recombinant C-terminal deleted HBc (HBc $\Delta$ ) molecules that are capable of assembling into capsids and do not pack viral RNA within their capsids. Zlotnick teaches that an addition of Cys at the C-terminus of HBc $\Delta$  can enhance the stability of HBc $\Delta$  (p. 9558).

30. One of ordinary skill in the art would have been motivated to combine the teachings of Birkett with that of Zlotnick in order to make an HBc $\Delta$  molecule that could present an epitope *via* a side-chain. One would have been motivated to do so, and would have had a reasonable expectation of success, given the knowledge that both HBc and HBc $\Delta$  have been successfully used for displaying heterologous epitopes on Hbc particles, as taught by Birkett, and given the knowledge that methods for operatively linking individual haptens to polypeptides through an amino acid residue side chain to form an immunogenic conjugate are well known in the art, as taught by Birkett, see e.g. col. 13

Art Unit: 1648

and 14, Therefore, the instant claims would have been *prima facie* obvious over Claims 1-19 of U.S. Patent No. 6,231,864 ('864), in view of Zlotnick.

***Remarks***

31 No claim is allowed.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bo Peng, Ph.D. whose telephone number is 571-272-5542. The examiner can normally be reached on M-F, 9-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, Ph. D. can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

/Bo Peng/  
Patent Examiner, AU1648